Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Immunotherapeutic Potential of m6A-Modifiers in Controlling Acute Myeloid Leukemia

Version 1 : Received: 8 May 2021 / Approved: 10 May 2021 / Online: 10 May 2021 (13:53:12 CEST)

A peer-reviewed article of this Preprint also exists.

Kumar, S.; Nagpal, R.; Kumar, A.; Ashraf, M.U.; Bae, Y.-S. Immunotherapeutic Potential of m6A-Modifiers and microRNAs in Controlling Acute Myeloid Leukaemia. Biomedicines 2021, 9, 690. Kumar, S.; Nagpal, R.; Kumar, A.; Ashraf, M.U.; Bae, Y.-S. Immunotherapeutic Potential of m6A-Modifiers and microRNAs in Controlling Acute Myeloid Leukaemia. Biomedicines 2021, 9, 690.

Journal reference: Biomedicines 2021, 9, 690
DOI: 10.3390/biomedicines9060690

Abstract

Epigenetic alterations have contributed greatly to human carcinogenesis. Conventional epigenetic studies have been predominantly focused on DNA methylation, histone modifications and chromatin remodelling. However, recently, RNA modification (m6A-methylation) also termed ‘epitranscriptomics’ has emerged as a new layer of epigenetic regulation due to its diverse role in various biological processes. In this review, we have summarized the therapeutic potential of m6A-modifiers in controlling haematological disorders especially acute myeloid leukemia (AML). It is a type of blood cancer affecting specific subsets of blood-forming hematopoietic stem/progenitor cells (HSPCs) which proliferate rapidly and acquire self-renewable capacities with impaired terminal cell-differentiation and apoptosis leading to abnormal accumulation of white blood cells, and thus an alternative therapeutic approach is required urgently. Here, we have described how RNA m6A-modification machineries EEE (Editor/writer: Mettl3, Mettl14; Eraser/remover: FTO, ALKBH5 and Effector/reader: YTHDF-1/2) could be reformed into potential druggable candidate or as RNA modifying drug (RMD) to treat leukemia. Moreover, we have shed-light on the role of microRNA and suppressor of cytokine signalling (SOCS/CISH) in increasing anti-tumor immunity towards leukemia. We anticipate, our investigation will provide a fundamental knowledge in nurturing the potential of RNA modifiers in discovering novel therapeutics or immunotherapeutic procedures.

Subject Areas

Epitranscriptomics, acute myeloid leukemia, microRNA, CISH, Immunotherapeutics.

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.